SHANGHAI, October 11, 2022 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global contract research, development and manufacturing company (CRDMO), and Toregem BioPharma, a biotech startup University of Kyotoannounced today that they have signed a Memorandum of Understanding (MOU) to form a strategic partnership in the development of TRG035, a monoclonal antibody targeting USAG-1 for the treatment of congenital adentia.

Under the terms of the partnership, Toregem BioPharma will have access to WuXi Biologics’ integrated CMC services in cell line development, cell banking and testing services, cell culture development, GMP biologics manufacturing, bioassay development and related services. WuXi Biologics will support Toregem BioPharma on the TRG035 project for its Investigational New Drug (IND) application.

“We are excited to be collaborating with WuXi Biologics as they are experienced in enabling universities to transform advanced technologies into promising products,” said Dr. Honoka Kiso, CEO of Toregem BioPharma. “By leveraging WuXi Biologics’ extensive IND-ready capabilities and large global footprint with extensive GMP manufacturing capabilities, Toregem BioPharma will be able to focus on realizing and maximizing the therapeutic potential of TRG035. WuXi Biologics is the best partner for us as we move forward to conduct the clinical study and realize the eventual commercialization of our unique product. We look forward to bringing this dental regeneration drug to the global market and treating patients around the world.”

DR Chris ChenCEO of WuXi Biologics, commented: “We are very excited to partner with Toregem BioPharma and this is one of the first integrated CMC projects in Japan which we have supported – with our integrated services and experience – from the early academic research phase to the clinical phase. WuXi Biologics is proud to support all kinds of global partners to bring new biologics solutions to patients in…